Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia

Schizophrenia Research

Volumn 146, Issue 1-3, 2013, Pages 231-237

  Lin, Chieh Hsin ^a,b   Huang, Chieh Liang ^c   Chang, Yue Cune ^d   Chen, Po Wei ^e   Lin, Chun Yuan ^a,f,g   Tsai, Guochuan E ^h   Lane, Hsien Yuan ^a,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAMKANG UNIVERSITY   (Taiwan)

^e Department of Psychiatry   (Taiwan)

^f Chang Hua Hospital   (Taiwan)

^g NATIONAL CHANGHUA UNIVERSITY OF EDUCATION   (Taiwan)

^h HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Clinical symptoms; Functional outcome; Neurocognition; Schizophrenia; Social cognition; Structural equation modeling

Indexed keywords

ADULT; ARTICLE; CHINESE; COGNITION; DEPRESSION; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; NEUROCOGNITION; NEUROPSYCHOLOGICAL TEST; POSITIVE SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SOCIAL COGNITION; STRUCTURAL EQUATION MODELING;

ADULT; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, PSYCHOLOGICAL; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOTROPIC DRUGS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR;

EID: 84875947054     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.02.009     Document Type: Article

References (58)

1. Addington J., Girard T.A., Christensen B.K., Addington D. Social cognition mediates illness-related and cognitive influences on social function in patients with schizophrenia-spectrum disorders. J. Psychiatry Neurosci. 2010, 35(1):49-54.
2. American Psychiatric Association Structured Clinical Interview for DSM-IV 1994, American Psychiatric Press, Washington DC.
3. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry Suppl. 1989, 7:49-58.
4. Andresen R., Oades L., Caputi P. The experience of recovery from schizophrenia: towards an empirically validated stage model. Aust. N. Z. J. Psychiatry 2003, 37(5):586-594.
5. Arbuckle J. Amos 7.0 User's Guide 2006, AMOS Development Corporation, Spring House (PA).
6. Bentler P., Chou C.P. Practical issues in structural modeling. Sociol. Methods Res. 1987, 16(1):78-117.
7. Brissos S., Dias V.V., Balanza-Martinez V., Carita A.I., Figueira M.L. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr. Res. 2011, 129(2-3):133-136.
8. Chen W.J., Liu S.K., Chang C.J., Lien Y.J., Chang Y.H., Hwu H.G. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am. J. Psychiatry 1998, 155(9):1214-1220.
9. Craig T., Fennig S., Tanenberg-Karant M., Bromet E.J. Six-month clinical status as a predictor of 24-month clinical outcome in first-admission patients with schizophrenia. Ann. Clin. Psychiatry 1999, 11(4):197-203.
10. Eack S.M., Greeno C.G., Pogue-Geile M.F., Newhill C.E., Hogarty G.E., Keshavan M.S. Assessing social-cognitive deficits in schizophrenia with the Mayer-Salovey-Caruso Emotional Intelligence Test. Schizophr. Bull. 2010, 36(2):370-380.
11. Fett A.K., Viechtbauer W., Dominguez M.D., Penn D.L., van Os J., Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci. Biobehav. Rev. 2011, 35(3):573-588.
12. Gard D.E., Fisher M., Garrett C., Genevsky A., Vinogradov S. Motivation and its relationship to neurocognition, social cognition, and functional outcome in schizophrenia. Schizophr. Res. 2009, 115(1):74-81.
13. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. Am. J. Psychiatry 2010, 167(6):686-693.
14. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26(1):119-136.
15. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., Fenton W.S., Frese F., Goldberg T.E., Heaton R.K., Keefe R.S., Kern R.S., Kraemer H., Stover E., Weinberger D.R., Zalcman S., Marder S.R. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 2004, 56(5):301-307.
16. Green M.F., Olivier B., Crawley J.N., Penn D.L., Silverstein S. Social cognition in schizophrenia: recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference. Schizophr. Bull. 2005, 31(4):882-887.
17. Green M.F., Hellemann G., Horan W.P., Lee J., Wynn J.K. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch. Gen. Psychiatry 2012, 1-9.
18. Hair J., Anderson R.E., Tatham R.L., Black W. Multivariate Data Analysis 1998, Prentice-Hall, Englewood Cliffs, NJ.
19. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
20. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10(3):388-398.
21. Hofer A., Benecke C., Edlinger M., Huber R., Kemmler G., Rettenbacher M.A., Schleich G., Wolfgang Fleischhacker W. Facial emotion recognition and its relationship to symptomatic, subjective, and functional outcomes in outpatients with chronic schizophrenia. Eur. Psychiatry 2009, 24(1):27-32.
22. Horan W.P., Green M.F., Degroot M., Fiske A., Hellemann G., Kee K., Kern R.S., Lee J., Sergi M.J., Subotnik K.L., Sugar C.A., Ventura J., Nuechterlein K.H. Social cognition in schizophrenia, part 2: 12-month stability and prediction of functional outcome in first-episode patients. Schizophr. Bull. 2012, 38(4):865-872.
23. Hoyle R. Structural Equation Modeling: Concepts, Issues And Applications 1995, Sage, Thousand Oaks (CA).
24. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
25. Keefe R.S., Buchanan R.W., Marder S.R., Schooler N.R., Dugar A., Zivkov M., Stewart M. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?. Schizophr. Bull. 2011, 39(2):417-435.
26. Lambert M., Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004, 18(Suppl. 2):5-17. (discussion 41-13).
27. Lane H.Y., Liu Y.C., Huang C.L., Chang Y.C., Liau C.H., Perng C.H., Tsai G.E. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol. Psychiatry 2008, 63(1):9-12.
28. Lane H.Y., Lin C.H., Huang Y.J., Liao C.H., Chang Y.C., Tsai G.E. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol. 2010, 13(4):451-460.
29. Lo C.H., Tsai G.E., Liao C.H., Wang M.Y., Chang J.P., Tsuang H.C., Lane H.Y. Emotional management and 5-HT2A receptor gene variance in patients with schizophrenia. Biol. Psychol. 2010, 83(2):79-83.
30. Ma W.F., Tsai G.E., Chang J.P., Lane H.Y. Reliability and validity of three Chinese-version tasks of Mayer-Salovey-Caruso Emotional Intelligence Test. J. Clin. Nurs. 2010, 19(17-18):2656-2658.
31. Mayer J.D., Salovey P., Caruso D.R., Sitarenios G. Measuring emotional intelligence with the MSCEIT V2.0. Emotion 2003, 3(1):97-105.
32. Mehta U.M., Thirthalli J., Gangadhar B.N., Keshavan M.S. Need for culture specific tools to assess social cognition in schizophrenia. Schizophr. Res. 2011, 133(1-3):255-256.
33. Milev P., Ho B.C., Arndt S., Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 2005, 162(3):495-506.
34. Nakagami E., Xie B., Hoe M., Brekke J.S. Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects. Schizophr. Res. 2008, 105(1-3):95-104.
35. Nakagami E., Hoe M., Brekke J.S. The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia. Schizophr. Bull. 2010, 36(5):935-948.
36. Narvaez J.M., Twamley E.W., McKibbin C.L., Heaton R.K., Patterson T.L. Subjective and objective quality of life in schizophrenia. Schizophr. Res. 2008, 98(1-3):201-208.
37. Rabinowitz J., Levine S.Z., Garibaldi G., Bugarski-Kirola D., Berardo C.G., Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr. Res. 2012, 137(1-3):147-150.
38. Reitan R.M. Validity of the Trail Making Test as an indicator of organic brain damage. Percept. Mot. Ski. 1958, 8:271-276.
39. Schennach-Wolff R., Jager M., Seemuller F., Obermeier M., Messer T., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Huff W., Heuser I., Maier W., Lemke M.R., Ruther E., Buchkremer G., Gastpar M., Moller H.J., Riedel M. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr. Res. 2009, 113(2-3):210-217.
40. Schennach-Wolff R., Jager M., Obermeier M., Schmauss M., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Klosterkotter J., Heuser I., Kuhn K.U., Lemke M.R., Ruther E., Klingberg S., Gastpar M., Seemuller F., Moller H.J., Riedel M. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?. World J. Biol. Psychiatry 2010, 11(5):729-738.
41. Schmidt S.J., Mueller D.R., Roder V. Social cognition as a mediator variable between neurocognition and functional outcome in schizophrenia: empirical review and new results by structural equation modeling. Schizophr. Bull. 2011, 37(Suppl. 2):S41-S54.
42. Sergi M.J., Rassovsky Y., Nuechterlein K.H., Green M.F. Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia. Am. J. Psychiatry 2006, 163(3):448-454.
43. Sergi M.J., Rassovsky Y., Widmark C., Reist C., Erhart S., Braff D.L., Marder S.R., Green M.F. Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr. Res. 2007, 90(1-3):316-324.
44. Silver H., Feldman P., Bilker W., Gur R.C. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am. J. Psychiatry 2003, 160(10):1809-1816.
45. Sim K., Chan Y.H., Chua T.H., Mahendran R., Chong S.A., McGorry P. Physical comorbidity, insight, quality of life and global functioning in first episode schizophrenia: a 24-month, longitudinal outcome study. Schizophr. Res. 2006, 88(1-3):82-89.
46. Smith T.E., Hull J.W., Goodman M., Hedayat-Harris A., Willson D.F., Israel L.M., Munich R.L. The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J. Nerv. Ment. Dis. 1999, 187(2):102-108.
47. Startup M., Jackson M.C., Bendix S. The concurrent validity of the Global Assessment of Functioning (GAF). Br. J. Clin. Psychol. 2002, 41(Pt 4):417-422.
48. Tomotake M. Quality of life and its predictors in people with schizophrenia. J. Med. Investig. 2011, 58(3-4):167-174.
49. van Hooren S., Versmissen D., Janssen I., Myin-Germeys I.a, Campo J., Mengelers R., van Os J., Krabbendam L. Social cognition and neurocognition as independent domains in psychosis. Schizophr. Res. 2008, 103(1-3):257-265.
50. Vauth R., Rusch N., Wirtz M., Corrigan P.W. Does social cognition influence the relation between neurocognitive deficits and vocational functioning in schizophrenia?. Psychiatry Res. 2004, 128(2):155-165.
51. Ventura J., Hellemann G.S., Thames A.D., Koellner V., Nuechterlein K.H. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr. Res. 2009, 113(2-3):189-199.
52. Ventura J., Wood R.C., Hellemann G.S. Symptom domains and neurocognitive functioning can help differentiate social cognitive processes in schizophrenia: a meta-analysis. Schizophr. Bull. 2011, 39(1):102-111.
53. Wagner, M., Schulze-Rauschenbach, S., Petrovsky, N., Brinkmeyer, J., von der Goltz, C., Grunder, G., Spreckelmeyer, K.N., Wienker, T., Diaz-Lacava, A., Mobascher, A., Dahmen, N., Clepce, M., Thuerauf, N., Kiefer, F., de Millas, J.W., Gallinat, J., Winterer, G., in press. Neurocognitive impairments in non-deprived smokers-results from a population-based multi-center study on smoking-related behavior. Addict. Biol. [Electronic publication ahead of print]. http://dx.doi.org/10.1111/j.1369-1600.2011.00429.x.
54. Wechsler D. Wechsler Intelligence Scale For Child 1991, Psychological Association, San Antonio, TX. 3rd ed.
55. Wechsler D. Wechsler Adult Intelligence Scale 1997, Psychological Association, San Antonio, TX. 3rd ed.
56. Wechsler D. Wechsler Memory Scale 1997, Psychological Association, San Antonio, TX. 3rd ed.
57. Woon P.S., Chia M.Y., Chan W.Y., Sim K. Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(3):463-468.
58. Zhang X.Y., Chen da C., Xiu M.H., Haile C.N., Sun H., Lu L., Kosten T.A., Kosten T.R. Cigarette smoking and cognitive function in Chinese male schizophrenia: a case-control study. PLoS One 2012, 7(5):e36563.